Literature DB >> 10973245

A transactivation-deficient mouse model provides insights into Trp53 regulation and function.

G S Jimenez1, M Nister, J M Stommel, M Beeche, E A Barcarse, X Q Zhang, S O'Gorman, G M Wahl.   

Abstract

The gene Trp53 is among the most frequently mutated and studied genes in human cancer, but the mechanisms by which it suppresses tumour formation remain unclear. We generated mice with an allele encoding changes at Leu25 and Trp26, known to be essential for transcriptional transactivation and Mdm2 binding, to enable analyses of Trp53 structure and function in vivo. The mutant Trp53 was abundant, its level was not affected by DNA damage and it bound DNA constitutively; however, it showed defects in cell-cycle regulation and apoptosis. Both mutant and Trp53-null mouse embryonic fibroblasts (MEFs) were readily transformed by oncogenes, and the corresponding mice were prone to tumours. We conclude that the determining pathway for Trp53 tumour-suppressor function in mice requires the transactivation domain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973245     DOI: 10.1038/79152

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  49 in total

Review 1.  DNA replication blockade impairs p53-transactivation.

Authors:  R Takimoto; W S El-Deiry
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

3.  Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function.

Authors:  Shih-Shun Chen; Pi-Chu Chang; Yu-Wen Cheng; Fen-Mei Tang; Young-Sun Lin
Journal:  EMBO J       Date:  2002-09-02       Impact factor: 11.598

4.  Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein.

Authors:  Kristine McKinney; Carol Prives
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

5.  p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance.

Authors:  Zaineb R Abdul Razak; Robert J Varkonyi; Michelle Kulp-McEliece; Corrado Caslini; Joseph R Testa; Maureen E Murphy; Dominique Broccoli
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

6.  Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes.

Authors:  Nathan P Gomes; Joaquín M Espinosa
Journal:  Cell Cycle       Date:  2010-09-13       Impact factor: 4.534

7.  Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage.

Authors:  Connie Chao; Zhiqun Wu; Sharlyn J Mazur; Helena Borges; Matteo Rossi; Tongxiang Lin; Jean Y J Wang; Carl W Anderson; Ettore Appella; Yang Xu
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

8.  DNA substrate dependence of p53-mediated regulation of double-strand break repair.

Authors:  Nuray Akyüz; Gisa S Boehden; Silke Süsse; Andreas Rimek; Ute Preuss; Karl-Heinz Scheidtmann; Lisa Wiesmüller
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

9.  Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.

Authors:  Natalia Issaeva; Assaf Friedler; Przemyslaw Bozko; Klas G Wiman; Alan R Fersht; Galina Selivanova
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

10.  p53-dependent inhibition of FKHRL1 in response to DNA damage through protein kinase SGK1.

Authors:  Han You; YingJu Jang; Annick Itie You-Ten; Hitoshi Okada; Jennifer Liepa; Andrew Wakeham; Kathrin Zaugg; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.